It is evidently known that chronic inflammatory process in the bronchi of patients with bronchial asthma is associated with the emergence and progression of airway remodeling, resulting in irreversible obstruction. However, the exact mechanisms of connection between inflammation and airway remodeling are not very well understood and that is the reason for delay of development new specific targeted drugs aimed to inhibit the process of inflammation and remodeling. Therefore, our goal was aimed to analyze and systematize data on the role of matrix metalloproteinases in the occurrence of airway remodeling in patients with bronchial asthma and the possibility of therapeutic effects on this process.
Materials and methods: search for information on the role and mechanisms of influence of matrix metalloproteinases on airway remodeling processes in patients with bronchial asthma and the possibility of its pharmacological correction in electronic databases such as PubMed and Google Scholar over the past 25 years.
Results. Matrix metalloproteinase-9 and tissue proteinase-1 inhibitor have been shown to play the most important role in airway remodeling in the presence of bronchial asthma, supported by numerous experimental and clinical studies. Much attention is paid to the comparison of these indicators in bronchoalveolar lavage, induced sputum and blood on the background of exacerbation and in the presence of a stable course of the disease. The analysis of their content depending on the severity of the course, dysfunction of external respiration and the degree of reversibility of bronchial obstruction. Studies of the possibility of drug effects on the content of remodeling markers have shown low clinical efficacy. The results are contradictory, but most of them prove the important role of matrix metalloproteinase-9, tissue protease inhibitor-1 and their relationship in the occurrence and progression of airway remodeling and, consequently, the severity of the disease, which dictates the need to develop new additional treatments.
2. Guida G, Riccio AM. Immune induction of airway remodeling. Semin. Immunol. 2019;46:341–346. doi: 10.1016/j.smim.2019.101346.
3. Ingram JL, Huggins MJ, Church TD. Airway fibroblasts in asthma manifest an invasive phenotype. Am. J. Respir. Crit. Care Med. 2011;183(12):1625–1632. doi: 10.1164/rccm.201009-1452OC.
4. Fixman ED, Stewart A, Martin JG. Basic mechanisms of development of airway structural changes in asthma. Eur. Respir. J. 2007;29:379–389. doi: 10.1183/09031936.00053506.
5. Boulet LP. Airway remodeling in asthma: update on mechanisms and therapeutic approaches. Curr. Opin. Pulm. Med. 2018;24:56–62. doi: 10.1097/MCP.0000000000000441.
6. Firszt R, Francisco D, Church TD. Interleukin-13 induces collagen type-1 expression through matrix metalloproteinase-2 and transforming growth factor-beta1 in airway fibroblasts in asthma. Eur. Respir. J. 2014;43(2):464–473. doi: 10.1183/09031936.00068712.
7. Shifren A, Witt C, Christie C. Mechanisms of remodeling in asthmatic airways. J. Allergy (Cairo). 2012;31(60):49. doi: 10.1155/2012/316049.
8. Brillet PY, Debray MP, Golmard JL. Computed tomography assessment of airways throughout bronchial tree demonstrates airway narrowing in severe asthma. Acad. Radiol. 2015;22(6):734–742. doi: 10.1016/j.acra.2014.12.026.
9. Stumm CL, Halcsik E, Landgraf RG. Lung remodeling in a mouse model of asthma involves a balance between TGF-B1 and BMP-7. PLoS One. 2014;9(4):56–59.
10. Saglani S, Lloyd CM. Novel concepts in airway inflammation and remodelling in asthma. Eur. Respir J. 2015;46:1796–1804. doi: 10.1183/13993003.01196-2014
11. Al-Muhsen S, Johnson JR, Hamid Q. Remodeling in asthma. J. Allergy Clin. Immunol. 2011;128:451–462.
12. Zhang YY, Xu HZ, Bao XE. Detection and Clinical Significance of a Potential Mediator of Airway Remodeling in Preschool Wheezy Children. HK J. Paediatr. (New Series). 2014;19:63–70.
13. Ohbayashi H, Shimokata K. Matrix metalloproteinase-9 and airway remodeling in asthma. Curr. Drug Targets. 2005;4(2):177–181. doi: 10.2174/1568010053586246
14. Polosa R, Bellinvia S, Caruso M. Weekly low-dose methotrexate for reduction of Global Initiative for Asthma Step 5 treatment in severe refractory asthma: study protocol for a randomized controlled trial. Trials. 2014;15:492. doi: 10.1186/1745-6215-15-492
15. Koloze MT. The Role Of Matrix Metalloproteinases (MMPs) And their proteolytic degradation of chemokines in the lung submitted in partial fulfillment of the requirements for the degree of master of science thesis advisor: Dr. Tracey L. Bonfield Department Of Pathology Case Western Reserve University May, 2010. Retrieved from: https://etd.ohiolink.edu/apexprod/rws_etd/send_file/send?accession=case1269959847&disposition=inline.
16. Chung FT, Huang HY, Lo CY. Increased ratio of matrix metalloproteinase-9 (MMP-9)/tissue inhibitor metalloproteinase-1 from alveolar macrophages in chronic asthma with a fast decline in FEV1 at 5-year follow-up. J. Clin. Med. 2019;8:14–51. https://doi.org/10.3390/jcm8091451.
17. Castano R, Miedinger D, Maghni K. Matrix metalloproteinase-9 increases in the sputum from allergic occupational asthma patients after specific inhalation challenge. Int. Arch. Allergy Immunol. 2013;160:161–164. doi: 10.1159/000339737.
18. Mohamed NF, Hala M. Interplay between matrix metalloproteinase-9 and tissue inhibitor of matrix metalloproteinase-1 in acute asthma exacerbation and airway remodeling. Egypt. J. Chest. Dis. Tuberc. 2012;61(3):35–39.
19. Kariyawasam HH, Pegorier S, Barkans J. Activin and transforming growth factor-beta signaling pathways are activated after allergen challenge in mild asthma. J. Allergy Clin. Immunol. 2009;(124):454–462. doi: 10.1016/j.jaci.2009.06.022.
20. Rohani MG, Parks WC. Matrix remodeling by MMPs during wound repair. Matrix. Biol. 2015;44:113–121. doi: 10.1016/j.matbio.2015.03.002.
21. Nissinen L, Kahari VM. Matrix metalloproteinases in inflammation. Biochim. Biophys. Acta. 2014;1840(8):2571–2580. doi: 10.1016/j.bbagen.2014.03.007.
22. Giannandrea M, Parks WC. Diverse functions of matrix metalloproteinases during fibrosis. Dis. Model. Mech. 2014;7(2):193–203. doi: 10.1242/dmm.012062.
23. Zhang J, Dong L. Personalized treatment and biomarker for airway remodeling. J. Thorac. Dis. 2020;12(10):6090–6101.
24. Cataldo D, Bettiol J, Noel A. Matrix metalloproteinase-9 but not tissue inhibitor of matrix metalloproteinase-1, increases in the sputum of allergic asthmatic patients after allergen challenge. Chest. 2002;122:1553–1559. doi: 10.1378/chest.122.5.1553.
25. Sands MF, Ohtake PJ, Mahajan SD. Tissue inhibitor of metalloproteinase-1 modulates allergic lung inflammation in murine asthma. Clin. Immunol. 2009;130(2):186–198. doi: 10.1016/j.clim.2008.08.029
26. Corry DB, Kiss A, Song LZ. Overlapping and independent contributions of MMP2 and MMP9 to lung allergic inflammatory cell egression through decreased CC chemokines. FASEB J. 2004;18(9):995–997. doi: 10.1096/fj.03-1412fje.
27. Vermaelen KY, Cataldo D, Tournoy K. Matrix metalloproteinase-9-mediated dendritic cell recruitment into the airways is a critical step in a mouse model of asthma. J Immunol. 2014;171(2):1016–1022. doi: 10.4049/jimmunol.171.2.1016.
28. Prado CM, Yano L, Rocha G. Effects of inducible nitric oxide synthase inhibition in bronchial vascular remodeling-induced by chronic allergic pulmonary inflammation. Exp. Lung. Res. 2011;37(5):259–268. doi: 10.3109/01902148.2010.538289.
29. Oshita Y, Koga T, Kamimura C. Increased circulating 92 k DA matrix metalloproteinase (MMP-9) activity exacerbation of asthma. Thorax. 2003;58:757–760. doi: 10.1136/thorax.58.9.757.
30. Bousquet J, Jeffery PK, Busse WW. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am. J. Respir. Crit. Care Med. 2000;161:1720–1745. doi: 10.1164/ajrccm.161.5.9903102.
31. Pavord ID, Beasley R, Agusti A. After asthma: redefining airways diseases. Lancet. 2018;391:350–400. doi: 10.1016/S0140-6736(17)30879-6.
32. Uwaezuoke SN, Ayuk AC, Eze JN. Severe bronchial asthma in children: a review of novel biomarkers used as predictors of the disease. J. Asthma Allergy. 2018;11:11–18. doi: 10.2147/JAA.S149577
33. Tanaka H, Masuda T, Tokuoka S. The effect of allergen-induced airway inflammation on airway remodeling in a murine model of allergic asthma. Inflamm. Res. 2001;50:616–624. doi: 10.1007/PL00000243
34. Vignola AM, Mirabella F, Costanzo G. Airway remodeling in asthma. Chest. 2003;123:417–422. doi: 10.1378/chest.123.3_suppl.417s
35. Wilson SJ, Rigden HM, Ward JA. The relationship between eosinophilia and airway remodelling in mild asthma. Clin. Exp. Allergy. 2013;43:1342–1350. doi: 10.1111/cea.12156
36. Dogu F, Yildiran A, Loglu D. Serum Transforming Growth Factor-ß 1(TGF-ß1),Matrix Metalloproteinase-2 (MMP-2),Matrix Metalloproteinase-9 (MMP-9) and Tissue Inhibitors of Metalloproteinase (TIMP-1) Levels in Childhood Asthma. Turk. J. Med. Sci. 2008;38:415–419.
37. Boulay ME, Prince P, Deschesnes F. Metalloproteinase-9 in induced sputum correlates with the severity of the late allergen-induced asthmatic response. Respiration. 2004;71:216–224. doi: 10.1159/000077418
38. Mattos W, Lim S, Russell R. Matrix metalloproteinase-9 expression in asthma: effect of asthma severity, allergen challenge and inhaled corticosteroids. Chest. 2002;122:1525–1543. doi: 10.1378/chest.122.5.1543
39. Chung H, Kimb S. Increased release of matrix metalloproteinase -9 and transforming growth factor-ß1 in the plasma of children with persistent asthma. J. Allergy Clin. Immunol. 2004;113:195.
40. Bergeron C, Tulic MK, Hamid Q. Airway remodelling in asthma: from benchside to clinical practice. Can. Respir. J. 2010;17:85–93. doi: 10.1155/2010/318029
41. Kelly EA, Jarjour NN. Role of matrix metalloproteinases in asthma. Curr. Opin. Pulm. Med. 2003;9:28–33. doi: 10.1097/00063198-200301000-00005
42. Mohamed-Hussein AA, Abdel-Aziz S. Imbalance between MMP-9 and its inhibitor is associated with increased airway wall thickness in uncontrolled asthmatics, Egypt. J. Bronchol. 2012;6:31–35.
43. Ko FW, Diba C, Roth M. A comparison of airway and serum matrix metalloproteinase-9 activity among normal subjects, asthmatic patients, and patients with asthmatic mucus hypersecretion. Chest. 2005;27(6):1919–1927. doi: 10.1378/chest.127.6.1919
44. Mohamed HO. Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) as non-invasive biomarkers of remodelling in asthma. J Pulm. Respir. Med. 2015;5:266. doi: 10.4172/2161-105X.1000266
45. Belleguic C, Corbel M, Germain N. Increased release of matrix metalloproteinase-9 in the plasma of acute severe asthmatic patients. Clin. Exp. Allergy. 2002;32(2):217–223. doi: 10.1046/j.1365-2222.2002.01219.x
46. Louis R, Lau LC, Bron AO. The relationship between airways inflammation and asthma severity. Am. J. Respir. Crit. Care Med. 2000;161:9–16. doi: 10.1164/ajrccm.161.1.9802048
47. Cundall M, Sun Y, Miranda C. Neutrophil-derived matrix metalloproteinase-9 is increased in severe asthma and poorly inhibited by glucocorticoids. J. Allergy Clin. Immunol. 2003;112:1064–1071. doi: 10.1016/j.jaci.2003.08.013
48. Ardi VC, Kupriyanova TA, Deryugina EI. Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis. Proc. Natl. Acad. Sci. U S A. 2007;104:262–267. doi: 10.1073/pnas.0706438104
49. Ventura I, Vega A, Chacon P. Neutrophils from allergic asthmatic patients produce and release metalloproteinase-9 upon direct exposure to allergens. Allergy. 2014;69:898–905. doi: 10.1111/all.12414
50. Hoshino M, Nakamura Y, Sim J. Bronchial subepithelial fibrosis and expression of matrix metalloproteinase-9 in asthmatic airway inflammation. J. Allergy Clin. Immunol. 1998;102:783–788. doi: 10.1016/s0091-6749(98)70018-1
51. Hoshino M, Takahashi M, Takai Y. Inhaled corticosteroids decrease subepithelial collagen deposition by modulation of balance between matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 expression in asthma. J. Allergy Clin. Immunol. 1999;104:356–363. doi: 10.1016/S0091-6749(99)70379-9
52. Higashimoto Y, Yamagata Y, Iwata T. Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Eur. Respir. J. 2005;25:885–890. doi: 10.1183/09031936.05.00092804
53. Karakoc GB, Yukselen A, Yilmaz M. Exhaled breath condensate MMP-9 level and its relationship with asthma severity and interleukin-4/10 levels in children. Ann. Allergy Asthma Immunol. 2012;108:300–304.
54. Kim JS, Kang JY, Ha JH. Expression of nerve growth factor and matrix metallopeptidase-9/tissue inhibitor of metalloproteinase-1 in asthmatic patients. J. Asthma. 2013;50:712–717. doi: 10.3109/02770903.2013.808664
55. Kumagai K, Ohno I, Imai K. The involvement of matrix metalloproteinases in basement membrane injury in a murine model of acute allergic airway inflammation. Clin. Exp. Allergy. 2002;32:1527–1534. doi: 10.1046/j.1365-2745.2002.01491.x
56. Barbaro MP, Spanevello A, Palladino GP. Exhaled matrix metalloproteinase-9 (MMP-9) in different biological phenotypes of asthma. Eur. J. Intern. Med. 2014;25(1):92–96. doi: 10.1016/j.ejim.2013.08.705
57. Felsen CN, Savariar EN, Whitney M. Detection and monitoring of localized matrix metalloproteinase upregulation in a murine model of asthma. Am. J. Physiol. Lung. Cell Mol. Physiol. 2014;306:764–774. doi: 10.1152/ajplung.00371.2013
58. Doherty GM, Kamath FC, Christie SN. Children with stable asthma have reduced airway matrix metalloproteinase-9 and matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio. Clin. Exp. Allergy. 2005;35:1168–1174. doi: 10.1111/j.1365-2222.2005.02326.x
59. Yadav SK, Shah SD, Penn RB. Give me a fork: can autophagy research solve the riddle of airway remodeling in asthma? Am. J. Respir. Cell Mol. Biol. 2019;60:494–496. doi: 10.1165/rcmb.2018-0353ED
60. Bullone M, Vargas A, Elce Y. Fluticasone/salmeterol reduces remodelling and neutrophilic inflammation in severe equine asthma. Sci. Rep. 2017;7:41–43.
61. Barton AK, Shety T, Bondzio A. Metalloproteinases and their inhibitors are influenced by inhalative glucocorticoid therapy in combination with environmental dust reduction in equine recurrent airway obstruction. BMC Vet. Res. 2016;12(1):282. doi: 10.1186/s12917-016-0915-1
62. Todorova L, Gürcan E, Westergren-Thorsson G. Budesonide/formoterol effects on metalloproteolytic balance in TGFbeta-activated human lung fibroblasts. Respir Med. 2009;103(11):1755–1763. doi: 10.1016/j.rmed.2009.03.018
63. Todorova L, Bjermer L, Miller-Larsson A. Relationship between matrix production by bronchial fibroblasts and lung function and AHR in asthma. Respir. Med. 2010;104(12):1799–1808. doi: 10.1016/j.rmed.2010.06.015
64. Todorova L, Bjermer L, Westergren-Thorsson G. TGFβ-induced matrix production by bronchial fibroblasts in asthma: budesonide and formoterol effects. Respir. Med. 2011;105(9):1296–1307. doi: 10.1016/j.rmed.2011.03.020
65. Matsuse H, Yamagishi T, Kodaka N. Tiotropium bromide as add-on therapy to inhaled corticosteroids for treating asthma. Expert. Opin. Pharmacother. 2015;16:1403 – 1409. doi: 10.1517/14656566.2015.1045877
66. Atkinson J, Senior RM. Matrix metalloproteinase-9 in lung remodeling. Am. J. Respir. Cell Mol. Biol. 2003;28:12–24. doi: 10.1165/rcmb.2002-0166TR
67. Goleva E, Hauk PJ, Boguniewicz J. Airway remodeling and lack of bronchodilator response in steroid-resistant asthma. J. Allergy Clin. Immunol. 2007;120(5):1065–1072. doi: 10.1016/j.jaci.2007.07.042
68. Obase Y, Rytilä P, Metso T. Effects of inhaled corticosteroids on metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in the airways of asthmatic children. Int. Arch. Allergy Immunol. 2010;151(3):247–254. doi: 10.1159/000242362
69. Grzela K, Zagorska W, Krejner A. Prolonged Treatment with Inhaled Corticosteroids does not Normalize High Activity of Matrix Metalloproteinase-9 in Exhaled Breath Condensates of Children with Asthma. Arch. Immunol. Ther. Exp. (Warsz). 2015;63(3):231–237. doi: 10.1007/s00005-015-0328-z
70. Grzela K, Zagórska W, Krejner A. Inhaled corticosteroids do not reduce initial high activity of matrix metalloproteinase (MMP)-9 in exhaled breath condensates of children with asthma exacerbation: a proof of concept study. Cent. Eur. J. Immunol. 2016;41(2):221–227. doi: 10.5114/ceji.2016.60998
71. Tenero L, Piazza M, Sandri M. Effect of montelukast on markers of airway remodeling in children with asthma. Allergy Asthma Proc. 2016;37(5):77–83. doi: 10.2500/aap.2016.37.3978
72. Royce SG, Li X, Tortorella S. Mechanistic insights into the contribution of epithelial damage to airway remodeling. Novel therapeutic targets for asthma. Am. J. Respir. Cell. Mol. Biol. 2014;50:180–192. doi: 10.1165/rcmb.2013-0008OC
73. Fang L, Wang X, Sun Q. IgE downregulates PTEN through microRNA-21-5p and stimulates airway smooth muscle cell remodeling. Int. J. Mol. Sci. 2019;20:875. doi: 10.3390/ijms20040875
74. Brightling CE, Chanez P, Leigh R. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir. Med. 2015;3:692–701. doi: 10.1016/S2213-2600(15)00197-6
75. Thomson NC. Recent developments in bronchial thermoplasty for severe asthma. J. Asthma Allergy. 2019;12:375–387. doi: 10.2147/JAA.S200912
76. Girodet PO, Dournes G, Thumerel M. Calcium channel blocker reduces airway remodeling in severe asthma. A proof-of-concept study. Am. J. Respir. Crit. Care Med. 2015;191:876–883. doi: 10.1164/rccm.201410-1874OC
77. Hong Z, Lin YM, Qin X. Serum MMP-9 is elevated in children with asthma. Mol. Med. Rep. 2012;5:462–464. doi: 10.3892/mmr.2011.656
This work is licensed under a Creative Commons Attribution 4.0 International License.